TL;DR
Co-treatment with brusatol and venetoclax strengthens cell cycle arrest, proliferation inhibition and apoptosis induction in AML cells compared with single drug treatment, and enhances the anti-leukemic activity of venetoclax.
It is suggested that pinocembrin prevents growth and induces pro-apoptotic effects in leukemic cells in vitro and in vivo validation and pharmacological optimization are required to determine its therapeutic potential in ALL.
Background: Non-small-cell lung cancer (NSCLC) is a major cause of cancer-related mortality. Current therapies are limited by drug resistance and adverse effects, highlighting the need for new strategies. Panduratin A (PA), a chalcone from Boesenbergia rotunda, has reported anticancer activity. This study investigated...
Chronic myeloid leukemia (CML) is driven by constitutive BCR–ABL1 activity and remains clinically challenging due to disease persistence and resistance to tyrosine kinase inhibitors (TKIs). SIRT1, a NAD+-dependent deacetylase, has been implicated in leukemic cell survival and chemoresistance through negative regulation...
It is demonstrated that Agrimol B significantly reduces leukemia burden in an Acute Monocytic Leukemia (AMoL) mouse model and suppresses proliferation, invasion, and migration of THP-1 cells in vitro.
Cutaneous T-cell lymphomas (CTCL) are skin-homing T-cell malignancies characterized by recurrent disease, therapeutic resistance and limited durable treatment responses in advanced stages. Although the proteasome inhibitor bortezomib has demonstrated activity in CTCL, the molecular pathways associated with its an...
Ruscogenin inhibits the malignant progression of nasopharyngeal carcinoma by downregulating KDM1A, thereby promoting apoptosis and ferroptosis and identifies the Rus-KDM1A axis as a promising therapeutic target for NPC treatment.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
